Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MPDL3280A: Phase I data

Data from 140 patients with locally advanced or metastatic solid tumors whose disease had progressed despite prior therapy in an open-label, dose-escalation, international Phase I trial showed that IV MPDL3280A once every 3 weeks

Read the full 343 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers